ライフサイエンスコーパス: probiotic

1 -HN019 (control+probiotic), and EP-HN019 (EP+probiotic).

2 t /placebo, and 27 receiving low FODMAP diet/probiotic).

3 e performed using a sham suspension (without probiotic).

4 as 18.49 for the classical and 18.53 for the probiotic.

5 ostridium difficile and an immune-modulatory probiotic.

6 delivery carrier for oral administration of probiotics.

7 at-killed LAB may be developed as anti-virus probiotics.

8 nfections related to lactobacilli containing probiotics.

9 ential application for improving efficacy of probiotics.

10 microbiome and a brief review of the use of probiotics.

11 ion in animals, targeted antibiotics, and/or probiotics.

12 management strategies, including the use of probiotics.

13 w, most research has focused on lactobacilli probiotics.

14 risk for adverse events among patients given probiotics.

15 e against this pathogen, represent potential probiotics.

16 Lactic acid bacteria (LAB) are the common probiotics.

17 phenols, carotenoids, vitamins, enzymes, and probiotics.

18 having seasonal allergies received either a probiotic (2 capsules/d, 1.5 billion colony-forming unit

19 .001), but not different between those given probiotic (207 +/- 98) or placebo (192 +/- 93) (P = .721

20 ng sham diet/placebo, 26 receiving sham diet/probiotic, 24 receiving low FODMAP diet /placebo, and 27

21 /g) (P = .008), but higher in patients given probiotic (9.1 rRNA genes/g) than patients given placebo

22 operationally referred to as next-generation probiotics, a concept that overlaps with the emerging co

23 dobacterium genus, which is commonly used in probiotics, accumulated in the ankylosing spondylitis pa

24 IL-6, IL-17, RANKL, OPG, and CCL2 - modulate probiotic action.

25 ts of herbs (such as cannabis and curcumin), probiotics, acupuncture, exercise, and mind-body therapy

26 detected in the guts of fish exposed to the probiotic after day 7, gut microbiota of the exposed til

27 orted for probiotic encapsulation to protect probiotics against GI tract insults and improve their ad

28 creted to improve the protective activity of probiotics against Salmonella pathogenesis in C. elegans

29 nswers for presumed "fat drugs" and slimming probiotics alike.

30 ere recruited; of whom 654 were allocated to probiotic and 661 to placebo.

31 eriod was divided into three stages: axenic, probiotic and active suspension.

32 human studies, including demonstration that probiotic and antibiotic therapies can suppress villus i

33 se (MTGase) in the development of innovative probiotic and non-probiotic yogurts with improved functi

34 We previously reported that probiotic and peanut oral immunotherapy (PPOIT) was effe

35 Probiotic and peanut oral immunotherapy has a sustained

36 Probiotic and peanut oral immunotherapy was associated w

37 mes did not differ significantly between the probiotic and placebo groups.

38 We review probiotic and prebiotic effects on emotional, cognitive,

39 Control, probiotic and synbiotic ice cream (10% w/w sheep milk cr

40 ndomized controlled trials evaluating use of probiotics and CDI in hospitalized adults taking antibio

41 These ternary blends protected the probiotics and enhanced their resistance to simulated ga

42 spite evidence for the beneficial effects of probiotics and low-fat dairy products, to our knowledge,

43 finition of psychobiotics be expanded beyond probiotics and prebiotics to include other means of infl

44 administration of synbiotics (combination of probiotics and prebiotics) and must have included an ass

45 ed MEDLINE, EMBASE, International Journal of Probiotics and Prebiotics, and The Cochrane Library data

46 without EP), EP (EP only), C-HN019 (control+probiotic), and EP-HN019 (EP+probiotic).

47 ological treatments, antidepressants, fiber, probiotics, and anticholinergics have not been adequatel

48 s of disease prevention, including vaccines, probiotics, and bacteriophages.

49 The most advanced approaches are antibodies, probiotics, and vaccines in phase 2 and phase 3 trials.

50 s, targeting of gut microbiota by innovative probiotics, antibiotics, and fecal transplant, in combin

51 subtilis in the gut during the seven days of probiotic application.

52 may provide a prototypic precursor-directed probiotic approach.

53 ine: Moderate-quality evidence suggests that probiotics are associated with lower rates of antibiotic

54 Probiotics are living microorganisms that provide benefi

55 and modulation of the gut microbiota (e.g., probiotics) as a potential treatment to decrease parasit

56 an antibiotic, is the co-administration of a probiotic associated with lower rates of antibiotic-asso

57 No probiotic-associated adverse events were reported.

58 of YloA-dependent adhesive properties of the probiotic B. subtilis natto (Bsn).

59 Supplementation with another probiotic, B. lactis NCC 2818, had no significant effect

60 nsion systems) or exposed to a single strain probiotic (Bacillus subtilis) added to the water.

61 the interactions between ingested, transient probiotic bacteria and intestinal bacterial communities

62 ron microscopy showed an interaction between probiotic bacteria and inulin fibre on synbiotic ice cre

63 Probiotic bacteria are generally regarded as safe to con

64 identification of a bioactive substance from probiotic bacteria could circumvent this difficulty.

65 taken a vital step towards understanding why probiotic bacteria increase iron absorption in the gastr

66 o-microcapsules of omega-3 rich tuna oil and probiotic bacteria L. casei were produced using whey pro

67 aluates effects of topical administration of probiotic bacteria of the genus Bifidobacterium on exper

68 ram-negative (Escherichia coli Nissle [EcN]) probiotic bacteria on virulent human rotavirus (VirHRV)

69 ular disease and it has been found that some probiotic bacteria possess cholesterol-lowering capabili

70 ne did not constitute a hurdle to lactic and probiotic bacteria survival, with presented values of ab

71 n caused severe perturbations of GM, reduced probiotic bacteria, and enriched pathogenic bacteria.

72 lained by the highly complex crosstalk among probiotic bacteria, the host's microbiota, and immune ce

73 ryptophan is a newly identified product from probiotic bacteria.

74 were used as encapsulating material for two probiotic bacteria: Bifidobacterium infantis and Lactoba

75 ere we demonstrate that microcins enable the probiotic bacterium Escherichia coli Nissle 1917 (EcN) t

76 t source fructose-asparagine (F-Asn), to the probiotic bacterium Escherichia coli Nissle 1917 (Nissle

77 pathway with redundant genes present in the probiotic bacterium L. lactis.

78 tegies, targeted public health measures, and probiotic-based preventions and therapies.

79 Probiotic baths of surface symbionts, Pseudomonas fluore

80 binding cassette (ABC) transporter from the probiotic Bifidobacterium animalis subsp. lactis Bl-04 b

81 We aimed to test the effectiveness of the probiotic Bifidobacterium breve BBG-001 to reduce necrot

82 placebo-controlled trial, we found that the probiotic BL reduces depression but not anxiety scores a

83 ntial wall material for targeted delivery of probiotics by altering its digestion.

84 BACKGROUND & AIMS: Probiotics can reduce symptoms of irritable bowel syndro

85 lostridia and Firmicutes could be studied as probiotic candidates for milk allergy therapy.

86 The probiotic cell count was higher than 6.5 and 7 log colon

87 enzyme also protects the viable starter and probiotic cells in yogurts.

88 is, we found evidence that administration of probiotics closer to the first dose of antibiotic reduce

89 The incidence of CDI in the probiotic cohort, 1.6% (54 of 3277), was lower than of c

90 he effect of SCFAs, prebiotics, and pre- and probiotic combinations (synbiotics) on systemic inflamma

91 Not only are probiotics considered beneficial to digestive health, bu

92 g efficacy of short-term feeding of the Lab4 probiotic consortium plus L. plantarum CUL66 in wild-typ

93 fat diet, 2-weeks supplementation with Lab4 probiotic consortium plus Lactobacillus plantarum CUL66

94 In this study, the ability of the Lab4 probiotic consortium to hydrolyse bile salts, assimilate

95 tank replication, suggesting that the early probiotic contact contributed to the subsequent observat

96 nd bacteremia from lactobacillus after using probiotics containing lactobacilli in the course of her

97 fect is warranted with the increasing use of probiotics containing lactobacilli.

98 nate respiration or treatment using targeted probiotics could prevent microbiota alterations and infl

99 Its enrichment with probiotics could thus further enhance its functional pro

100 cies and functions, for example, by pre- and probiotics, could enhance microbiome resilience and lead

101 Microbiological counts (probiotic count, survival after in vitro gastrointestina

102 entration of curing salts, the nature of the probiotic culture (free or immobilized Lactobacillus cas

103 and the supplementation of Prato cheese with probiotic cultures may be an effective alternative to th

104 The leading probiotics currently available to consumers are generall

105 potential alternative for the development of probiotic dairy products with reduced sodium content.

106 This histamine-producing probiotic decreased the number and size of colon tumors

107 ro treatment of mononuclear cells with these probiotics demonstrated that EcN, but not LGG, induced I

108 Future research should focus on optimal probiotic dose, species, and formulation.

109 e on the generation of volatile compounds in probiotic dry-fermented sausages was investigated.

110 n colonization with a commensal, potentially probiotic E. coli bacteriuria strain.

111 We engineered probiotic E. coli Nissle 1917, to express and secrete th

112 d by certain commensal, extraintestinal, and probiotic E. coli.

113 there has been no study which has evaluated probiotic effects on EoE inflammation.

114 efore represent critical new determinants of probiotic efficacy in clinical trials.

115 Probiotics encapsulated with the ternary blends incorpor

116 a seed and flaxseed are excellent sources of probiotic encapsulating agents.

117 ayer-by-layer (LbL) approach is reported for probiotic encapsulation to protect probiotics against GI

118 ptoms, although the mechanisms through which probiotics exert their beneficial effects are largely un

119 e been learned from working with traditional probiotics, explore the kinds of organisms that are like

120 unconjugated bile acids in the faeces of the probiotic-fed mice, together with modulation of hepatic

121 Probiotic feeding also decreased nesfatin-1 peptide in H

122 iometabolic effects of phenolics, dairy fat, probiotics, fermentation, coffee, tea, cocoa, eggs, spec

123 ggests that CB0313.1 may act as a beneficial probiotic for the prevention and treatment of hyperglyce

124 tudy highlight the potential for repurposing probiotics for the therapy of osteoporosis.

125 for alternatives to pharmaceuticals, such as probiotics, for the prevention of allergic disease.

126 4 weeks, along with a placebo or multistrain probiotic formulation, resulting in 4 groups (27 receivi

127 e early stage of AD were treated with SLAB51 probiotic formulation, thereby affecting the composition

128 y of delay in starting probiotics (P = .04); probiotics given within 2 days of antibiotic initiation

129 the percentage of women with mastitis in the probiotic group (25% [n = 14]) was significantly lower t

130 Those in the probiotic group (n = 55) ingested daily 9 log10 colony-f

131 randomisation, thus 650 were analysed in the probiotic group and 660 in the placebo group.

132 deaths occurred before discharge home in the probiotic group compared with 56 (9%) in the placebo gro

133 results for all parameters were seen in the probiotic group compared with the control group (P <0.00

134 61 infants (9%) in the probiotic group had necrotising enterocolitis compared w

135 g) E concentrations and Treg percentages.The probiotic group reported an improvement in the MRQLQ glo

136 s occurred, the milk bacterial counts in the probiotic group were significantly lower than those obta

137 (95% CI 0.68-1.27); 73 (11%) infants in the probiotics group had sepsis compared with 77 (12%) in th

138 -obesity group and lyophilized monocomponent probiotics groups (III-V).

139 roup II, MSG-obesity group) and treated with probiotics (groups III-VII).

140 The consumption of probiotics has become increasingly popular as a means to

141 Probiotics have become one of effective alternatives to

142 Probiotics have been hypothesized to affect immunologic

143 Given this scenario, probiotics have been suggested as a useful alternative f

144 Probiotics have shown beneficial effects on health and p

145 IGNIFICANCE STATEMENT Commercially available probiotics have the potential to modify visceral pain.

146 , easy answers (whether about antibiotics or probiotics) have again given way to an appreciation for

147 Live bacteria (such as probiotics) have long been used to modulate gut microbio

148 Synbiotics, a mixture of prebiotics and probiotics, have been used for the prevention and treatm

149 Developing genetically engineered probiotics holds great promise as a new therapeutic para

150 ot different between groups.This combination probiotic improved rhinoconjunctivitis-specific quality

151 alyzed the available data on the efficacy of probiotics in candidal colonization of host surfaces.

152 There is growing interest in the use of probiotics in periodontal therapy; however, until now, m

153 s have provided evidence for the efficacy of probiotics in preventing Clostridium difficile infection

154 required to establish safety and efficacy of probiotics in reducing fracture risk in people.

155 ls have also shown the beneficial effects of probiotics in reducing oral, vaginal, and enteric coloni

156 The efficacy of probiotics in the context of atopic diseases has been we

157 ectious diseases and for stably establishing probiotics in the gut.

158 The growth of probiotics in the presence of total, acidic or neutral p

159 te to significantly enhanced survival of LbL-probiotics in vivo.

160 dies are required to assess the viability of probiotics in yogurts protected using MTGase-mediated mi

161 ure was not affected by dietary fat level or probiotic inclusion.

162 Co-administration of the multistrain probiotic increased numbers of Bifidobacterium species,

163 community and provides insight into how the probiotic interacts to regulate a novel gene network inv

164 The probiotic intervention was B breve BBG-001 suspended in

165 where the rational design of next-generation probiotics is being actively pursued to prevent disease

166 known, but the role of Lactobacillus species probiotics is still controversial.

167 However, a concern for application of probiotics is the loss of viability during storage and g

168 In addition, mice received probiotic L. reuteri, or vehicle as a control, via oral

169 fects are long-lasting and not attenuated by probiotic L. reuteri.

170 Microbiological (lactic acid bacteria and probiotic Lactobacillus casei 01 counts and survival und

171 microbial Zn(II) acquisition from CP by the probiotic Lactobacillus plantarum and the opportunistic

172 their own natural commensals (including the probiotic Lactobacillus plantarum).

173 mmation, effects that can be attenuated with probiotic Lactobacillus reuteri.

174 rolyzed casein formula (EHCF) containing the probiotic Lactobacillus rhamnosus GG (LGG) can reduce th

175 an eight-day exposure of zebrafish larvae to probiotic Lactobacillus rhamnosus, high-throughput seque

176 vity of MOS was evaluated in vitro using two probiotic Lactobacillus strains.

177 tment of sex steroid-deficient mice with the probiotics Lactobacillus rhamnosus GG (LGG) or the comme

178 Two candidate probiotics, Lactococcus lactis NCC 2287 and Bifidobacter

179 With respect to the sensory acceptance, the probiotic low-sodium Minas cheese presented scores above

180 Probiotics may improve quality of life during allergy se

181 Probiotics may reduce necrotising enterocolitis and late

182 Probiotics may serve in the future as a worthy ally in t

183 acids to biogenic amines by gut microbes and probiotic-mediated suppression of colorectal neoplasia.

184 ght to identify and characterize a bioactive probiotic metabolite for potential prevention of allergi

185 Second, mechanisms whereby probiotic microorganisms can impart beneficial effects o

186 s (BB 12); and QC, co-culture with the three probiotic microorganisms.

187 s a feasible material for the development of probiotic microparticles with adequate physicochemical p

188 nd 50%) and addition of arginine (1% w/w) in probiotic Minas cheese was investigated.

189 rth of both alive (VII) and lyophilized (VI) probiotic mixture lead to a significant decrease by 69.5

190 ed monoprobiotic strains and the efficacy of probiotic mixture with the preference of alive probiotic

191 roximately by 22-25 % in groups treated with probiotic mixtures (VI, VII) compared to the MSG-obesity

192 For both alive and lyophilized probiotic mixtures, reduction of lobular inflammation wa

193 apply Lactobacillus rhamnosus GG (LGG) as a probiotic model to evaluate the effectiveness of this ap

194 and were assigned randomly to a test (SRP + probiotic, n = 14) or control (SRP + placebo, n = 14) gr

195 were taken from a subgroup (placebo, n = 37; probiotic, n = 35) at baseline and week 6 (predicted pea

196 doxically, this gene cluster is found in the probiotic Nissle 1917.

197 hat Lactobacillus fermentum, one of the main probiotics of the microbiota, exhibits an extraordinary

198 nal impact of daily treatment with the VSL#3 probiotic on cellular and humoral immunity and inflammat

199 ry, the mechanisms underlying the effects of probiotics on aging have rarely been assessed.

200 e is known about the impact of commonly used probiotics on human RV (HRV) infection.

201 Infants were randomly assigned (1:1) to probiotic or placebo via a minimisation algorithm random

202 either RCE (60 mg isoflavone aglycones/d and probiotics) or a masked placebo [control (CON)].RCE sign

203 n this report, we tested the hypothesis that probiotic organisms could compete for the preferred nutr

204 efficacy for every day of delay in starting probiotics (P = .04); probiotics given within 2 days of

205 nsumed raw food (P = 0.01), to have consumed probiotics (P = 0.002), or to have been given antibiotic

206 ber of well-controlled studies indicate that probiotics, particularly lactobacilli, suppressCandidagr

207 strointestinal (GI) tract through the use of probiotics (PBio) is a safe and well-tolerated approach

208 from Feta-type cheese and were screened for probiotic potential in a series of established in vitro

209 ternary blends reduced particle size of the probiotic powders thereby offering additional functional

210 s (l-arginine, yeast and oregano extract) on probiotic Prato cheese was investigated after 1, 30, and

211 Recently, the effectiveness of probiotics, prebiotics, and synbiotics in reducing posto

212 formula with additional active ingredients (probiotics, prebiotics, or both) (LPFA) and breastfed in

213 Several off-the-shelf probiotic preparations that include Bifidobacterium stra

214 therefore, both commensal microbiota and the probiotic product should be considered as possible sourc

215 nonantibiotic prophylactic measures such as probiotics, prokinetics, bile acids, statins, and hemato

216 ith the host as well as those with potential probiotic properties.

217 activation patterns that indicate that this probiotic reduces limbic reactivity.

218 Additionally and not unexpectedly, probiotics reversed hypogonadal osteopenia in sex steroi

219 of a Lactobacillus rhamnosus SP1-containing probiotic sachet as an adjunct to non-surgical therapy.

220 e a day for 3 months, of an L. rhamnosus SP1 probiotic sachet commenced after the last session of SRP

221 Classical and probiotic set yogurt were made using non-standard heat t

222 erms it is possible to produce classical and probiotic sheep's milk yogurt by using a non-standard te

223 The engineered probiotic shows in vivo prophylactic and therapeutic act

224 importance of diet on ingested strains with probiotic significance.

225 Secondary analyses examined the effects of probiotic species, dose, timing, formulation, duration,

226 and fidaxomicin) is a desired trait in such probiotic species, we screened several bacteria and iden

227 gle dose of exopolysaccharide (EPS) from the probiotic spore-forming bacterium Bacillus subtilis prot

228 encoding an anti-biofilm enzyme, and use the probiotic strain Escherichia coli Nissle 1917 as host.

229 n of yogurt, a standard yogurt culture and a probiotic strain Lactobacillus rhamnosus GG were used.

230 nsure a safe exploitation of the potentially probiotic strain.

231 n aqueous solution of a mixture of the three probiotic strains (2:1:1 Lactobacillus casei IMVB-7280,

232 ic "Symbiter" containing biomass of 14 alive probiotic strains (Lactobacillus + Lactococcus (6 x 10(1

233 Cheese is a suitable matrix to deliver probiotic strains but it contains a high amount of sodiu

234 The three camel milk probiotic strains Lb. reuteri-KX881777, Lb. plantarum-KX

235 Future UTI-preventive probiotic strains may benefit by retaining the escherich

236 Three probiotic strains namely Lactobacillus casei, Lactobacil

237 ity) of camel milk fermented with indigenous probiotic strains of Lactobacillus spp., compared with f

238 Supernatants from 13 of 37 tested probiotic strains showed immunoactivity.

239 The majority (11 out of 14) of the tested probiotic strains significantly grew in the neutral frac

240 ytic effects of adding isolated and combined probiotic strains to goat "coalho" cheese.

241 The potentially probiotic strains were added to the mixture in the DVS p

242 Two probiotic strains were selected for encapsulation (Lacto

243 To investigate the efficacy of different probiotic strains, their combinations and forms (alive o

244 obiotic mixture with the preference of alive probiotic strains.

245 own some promising results for prebiotic and probiotic strategies as prophylaxis or treatment of GVHD

246 Probiotic supernatants were screened for their ability t

247 nosus GG (LGG) or the commercially available probiotic supplement VSL#3 reduces gut permeability, dam

248 Early probiotic supplementation (at the age of 0-27 days) was

249 robiotic supplementation after 27 days or no probiotic supplementation (hazard ratio [HR], 0.66; 95%

250 isk of islet autoimmunity when compared with probiotic supplementation after 27 days or no probiotic

251 Details of infant feeding, including probiotic supplementation and infant formula use, were m

252 Early probiotic supplementation may reduce the risk of islet a

253 was being acknowledged by practices such as probiotic supplementation, e.g. after a course of antibi

254 The impact of probiotic-supplemented infant formula on the composition

255 Probiotic survival and viability after spray drying and

256 Significant changes in probiotic survival were observed; however, the sodium re

257 Microencapsulated probiotics survived well in simulated gastrointestinal c

258 the ceca of birds administered the modified probiotic than other treatment groups.

259 Our data further suggest that probiotics that decrease gut permeability have potential

260 The incorporation of putative probiotic - the L. helveticus, to ferment cream prior to

261 nd suggests novel metabolic targets for pre-/probiotics therapies.

262 Integration of antibiotic and probiotic therapy has the potential to lessen the public

263 characterization has revealed candidates for probiotic therapy.

264 hese results underline the capability of the probiotic to modulate the gut microbiota community and p

265 quence analysis evidenced the ability of the probiotic to modulate the microbial composition of the g

266 e composition and highlight the potential of probiotics to attenuate high-fat diet-related metabolic

267 d prescribing prophylactic vancomycin and/or probiotics to colonized patients to prevent progression

268 tract (RCE) rich in isoflavone aglycones and probiotics to concomitantly promote uptake and a favorab

269 n-pathogenic organisms and have been used as probiotics to prevent antibiotic associated diarrhea.

270 Long-term PPI users should not routinely use probiotics to prevent infection.

271 The development of next-generation probiotics to reestablish colonization resistance and el

272 s that can be developed into next-generation probiotics to reestablish or enhance colonization resist

273 dition to human milk, such as prebiotics and probiotics, to the management of high-risk infants.

274 ial effects of a bioavailable isoflavone and probiotic treatment against postmenopausal osteopenia.We

275 e extraction and analysis, immune responses, probiotic treatment and microbiota analysis.

276 TA plasticity, and behavior and suggest that probiotic treatment may relieve specific behavioral abno

277 cillus plantarum to determine the effects of probiotic treatment on structural and functional changes

278 with the control, fish gut microbiota under probiotic treatment was less affected by spatial differe

279 stage, through metamorphosis, and following probiotic treatment.

280 a in northern Finland and participating in a probiotic trial from October 1, 2009, through April 30,

281 nt analysis to study the association between probiotic use and islet autoimmunity, stratifying by cou

282 ction (CDI), but guidelines do not recommend probiotic use for prevention of CDI.

283 diarrheal history, as well as maternal age, probiotic use, and smoking.

284 further studies before any recommendation of probiotics use is made.

285 t asthma, although the results of studies of probiotics used together with prebiotics have been overa

286 The pooled relative risk of CDI in probiotic users was 0.42 (95% confidence interval, 0.30-

287 present work describes the encapsulation of probiotics using a by-product as wall material and a pro

288 l properties and enhanced significantly both probiotic viability and tolerance against simulated gast

289 The combination of probiotics, vitamins, and biological agents with AIT is

290 Conversely, feeding SCI mice commercial probiotics (VSL#3) enriched with lactic acid-producing b

291 The treatment with probiotics was started at the age of 1 month.

292 Meta-regression analysis demonstrated that probiotics were significantly more effective if given cl

293 ncapsulation system to preserve viability of probiotics when they are administrated orally and apply

294 This study sought to identify a probiotic which improves esophageal inflammation in expe

295 cs were previously defined as live bacteria (probiotics) which, when ingested, confer mental health b

296 eficial effect on weight loss of consuming a probiotic yogurt (PY) compared with a standard low-fat y

297 The use of a probiotic yogurt supplemented with B. animalis can have

298 the end of storage time of the classical and probiotic yogurt the totals of non-denatured whey protei

299 at originated from cultures in classical and probiotic yogurt were analysed during 21days of storage

300 development of innovative probiotic and non-probiotic yogurts with improved functional and quality c